Michael Kolodziej, MD, has joined Flatiron Health as national medical director, Managed Care Strategy.
Michael Kolodziej, MD, has joined Flatiron Health as national medical director, Managed Care Strategy. With his blended experience of a practicing oncologist and a payer, Kolodziej will potentiate the development of alternate payment programs for community oncology clinics.
Flatiron Health, which provides technology platforms to the oncology community, has been a pathbreaker in supporting oncologists as they adapt to new reimbursement models. At Aetna, Kolodziej actively worked with community oncology practices as they developed care delivery and payment programs such as medical homes. He was also involved in establishing a value-based medical home collaboration with the University of Chicago Medicine; the pilot project, which kicked off a year back, enrolled Aetna members who were receiving treatment for breast, lung, and colon cancer at the University.
In the press release, Flatiron Health’s cofounder and chief executive officer, Nat Turner, said of Kolodziej that he “brings a wealth of expertise across providers and commercial payers, and will be critical to Flatiron Health’s strategic growth as we continue to evolve in parallel with today’s changing reimbursement environment. We are thrilled to welcome him to our team and believe his deep knowledge will enable us to further develop our innovative value-based care solution for providers facing a growing number of alternative payment programs.”
According to Kolodziej, “Flatiron Health has the technology and analytics expertise to help payers and providers streamline these complex processes, and I am honored to help guide and grow our program for the benefit of the greater oncology community.”
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More